Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
ASH Presentation Of A Phase I Study Of REVLIMID(R) And VIDAZA(R) In Higher-Risk MDS Reports Combination Is ... (Medical News Today) |
Celgene International SÃ rl (NASDAQ: CELG) reported that results of a Phase I study presented today combining REVLIMID and VIDAZA in patients with higher-risk myelodysplastic syndromes (MDS) found that the combination of these two therapies is well tolerated and has high activity. The data were reported during the 50th Annual Meeting of the American Society of Hematology. |